Cortisone
Corticosteroids, plainGlucocorticoidsCorticosteroidCorticosteroid Hormone Receptor AgonistsGlucocorticoid Receptor AgonistsLipoxygenase InhibitorsCarbohydrate Metabolism AlterationDecreased Cellular MigrationDecreased Glucocorticoid SecretionDecreased Leukotriene ActivityDecreased Lysosomal FunctionDecreased Prostaglandin ActivityDecreased Protein SynthesisDecreased Thromboxane ActivityLipid Metabolism AlterationUS-FDASourced from openFDA
GET
/api/v1/drug/cortisoneMechanism of action
Sourced from openFDAMechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.
Corticosteroid Hormone ReceptorGlucocorticoid ReceptorLipoxygenase
Indications
Sourced from openFDA- Dry skin and dry mouth*
Dosage & administration
Sourced from openFDAAdults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.
Approval history
Sourced from openFDA- Oct 17, 1974ANDAANDA080694Chartwell Molecular
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
12,187 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Systemic Lupus Erythematosus6,16751%
- 2Pain6,14850%
- 3Pemphigus6,05650%
- 4Drug Ineffective6,04850%
- 5Alopecia5,99949%
- 6Rheumatoid Arthritis5,91249%
- 7Abdominal Discomfort5,89448%
- 8Fatigue5,58146%
- 9Glossodynia5,47045%
- 10Swelling5,33044%
- 11Hand Deformity5,06242%
- 12Wound4,88440%
- 13Rash4,86440%
- 14Arthropathy4,71639%
- 15Contraindicated Product Administered4,46437%
Literature
Recent PubMed references pinned to Cortisone as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Patient perceptions and knowledge of corticosteroid injections: A cross-sectional survey study.PloS one · 2026 · Chung J, Ramtin S, Koehler P, et al.PMID 41849285DOI 10.1371/journal.pone.0344201
- Determination of hydrocortisone and cortisone in artificial saliva by spray assisted fine droplet formation liquid phase microextraction coupled to LC-MS/MS.Scientific reports · 2026 · Gürsoy S, Bodur S, Atakol A, et al.PMID 41634132DOI 10.1038/s41598-026-38457-z
- Salivary Cortisone as a Potential Alternative to Cortisol in Periodontitis Severity Assessment.International journal of molecular sciences · 2026 · Dimitrov D, Mlachkova A, Dosseva-Panova V, et al.PMID 41596453DOI 10.3390/ijms27020805
- Hair cortisol/cortisone in combined oral contraceptive users: An exploratory analysis.Contraception · 2026 · Dorfling DS, Venter G, Erasmus E, et al.PMID 41274333DOI 10.1016/j.contraception.2025.111310
- From anatomy to therapy: the historical journey to cortisone.Reumatismo · 2026 · Damiani E, Marson P, Galassi FM, et al.PMID 41263019DOI 10.4081/reumatismo.2025.1935
- Cortisol-to-cortisone and testosterone-to-androstenedione concentration ratios in nails: Their determination methods based on LC/MS/MS and differences from the serum concentration ratios in the literature.Steroids · 2026 · Ishikawa H, Tanaka S, Shibata K, et al.PMID 41187891DOI 10.1016/j.steroids.2025.109707
- Application of a magnetic bead-assisted liquid chromatography-tandem mass spectrometry method for the simultaneous detection of aldosterone, cortisol, deoxycorticosterone, and cortisone in plasma.Journal of chromatography. A · 2025 · Tang Q, Yao H, Zhou Y, et al.PMID 41061599DOI 10.1016/j.chroma.2025.466429
- Reproductive toxicity of chronic exposure to cortisone in western mosquitofish (Gambusia affinis).Aquatic toxicology (Amsterdam, Netherlands) · 2025 · Ye M, Yang J, Cai Z, et al.PMID 41038008DOI 10.1016/j.aquatox.2025.107587
Clinical trials
The 10 most recently updated of 195 ClinicalTrials.gov registrations naming Cortisone as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting · Phase 2 · Interventional · 461 enrolled · National Cancer Institute (NCI)NCT04546399updated 2026-06-12
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruiting · Phase 1 · Phase 2 · Interventional · 16 enrolled · National Cancer Institute (NCI)NCT05896839updated 2026-06-12
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruiting · Phase 3 · Interventional · 1,875 enrolled · National Cancer Institute (NCI)NCT05675410updated 2026-06-12
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaActive not recruiting · Phase 3 · Interventional · 306 enrolled · National Cancer Institute (NCI)NCT00602641updated 2026-06-11
- Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID TrialNot yet recruiting · Phase 3 · Interventional · 102 enrolled · SWOG Cancer Research NetworkNCT07220187updated 2026-06-11
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruiting · Phase 2 · Interventional · 153 enrolled · National Cancer Institute (NCI)NCT06317662updated 2026-06-11
- Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin DiseaseCompleted · Phase 2 · Interventional · 188 enrolled · Children's Oncology GroupNCT00107198updated 2026-06-05
- Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasRecruiting · Phase 1 · Interventional · 20 enrolled · City of Hope Medical CenterNCT07278856updated 2026-06-05
- Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell LymphomaSuspended · Phase 1 · Interventional · 38 enrolled · Yazeed SawalhaNCT04850495updated 2026-06-04
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting · Phase 2 · Interventional · 222 enrolled · National Cancer Institute (NCI)NCT06124157updated 2026-06-03
Frequently asked questions
- How does Cortisone work?
- Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.
- What is Cortisone used for?
- According to FDA labeling, Cortisone carries indications including: Dry skin and dry mouth*. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Cortisone?
- Cortisone is classified as Corticosteroids, plain, Glucocorticoids, Corticosteroid, Corticosteroid Hormone Receptor Agonists, Glucocorticoid Receptor Agonists, Lipoxygenase Inhibitors, Carbohydrate Metabolism Alteration, Decreased Cellular Migration, Decreased Glucocorticoid Secretion, Decreased Leukotriene Activity, Decreased Lysosomal Function, Decreased Prostaglandin Activity, Decreased Protein Synthesis, Decreased Thromboxane Activity, Lipid Metabolism Alteration.
Note. Data for
cortisone is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.